Genmab — November 2023
-
-
https://ashpublications.org/blood/article/140/Supplement 1/7320/490109/Preliminary-Dose-Escalation-Results-from-a-Phase-1?searchresult=1 this was the ASH data last year from the dose escalation tox profile (outside of the 2 grade 5) does not look worse, and responses in the CD38 naive patients look better imo?
-
SB det var vel netop "prof" der solgte den ned. Solgte for ca 148 mio kr i 2 hug. Når man har den salgs penge placer i genmab, så administrere man mindst et 10-cifret beløb
-
For mig at se er biotech markedet smadret. Se data fra et selskab med mcap på $50 mln https://finance.yahoo.com/news/affimed-announces-oral-presentation-phase-130500854.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind